The of Immunotherapies
A Unique Approach
to Immunology
Alpine Immune Sciences is a clinical stage biopharmaceutical company dedicated to discovering and developing innovative, protein-based immunotherapies. Formed in 2014, we have created and advanced multiple product candidates into clinical trials for inflammatory/autoimmune diseases and cancer, formed collaborations with world-class partners, and built a robust development pipeline.
Our scientific platform consists of unique protein engineering strategies, including the directed evolution of immune proteins into novel, multi-targeted therapeutics. With such differentiated candidates, we hope to improve outcomes in patients with cancer and severe inflammatory and autoimmune diseases.
Join us in the discovery and development of next-generation immunotherapies.
Current job openingsLearn more about Alpine
Alpine’s Pipeline
We have a diverse pipeline. For more information on our ongoing clinical trials please refer to the clinical trials portion of our website. For additional information please refer to our corporate filings, corporate presentations, and scientific publications.
Latest News
Alpine Immune Sciences and Horizon Therapeutics plc Announce Exclusive License and Collaboration Agreement to Develop Novel Protein-Based Therapies for Autoimmune and Inflammatory Diseases
Alpine Immune Sciences, Inc. (Nasdaq: ALPN) and Horizon Therapeutics plc (Nasdaq: HZNP) today announced an exclusive license and collaboration agreement…
Alpine Immune Sciences Provides Corporate Update and Reports Third Quarter 2021 Financial Results
Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer and autoimmune/inflammatory diseases, today provided a corporate update and reported financial results…
Alpine Immune Sciences to Present ALPN-303 Data at American College of Rheumatology Convergence 2021 Annual Meeting
Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company, today announced a presentation in a Plenary session of the American College of Rheumatology (ACR) Convergence 2021 Annual Meeting…
